Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics

Peptides

Volumn 29, Issue 11, 2008, Pages 1878-1886

  Cassone, Marco ^a   Vogiatzi, Paraskevi ^a   La Montagna, Raffaele ^a   De Olivier Inacio, Vanessa ^b   Cudic, Predrag ^b   Wade, John D ^c   Otvos Jr , Laszlo ^a  

^a TEMPLE UNIVERSITY   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

A3 APO; Antimicrobial peptide; DnaK; Synergy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; COTRIMOXAZOLE; PEPTIDE A3 APO; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE; PROTEIN DNAK; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS SAPROPHYTICUS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BETA-GALACTOSIDASE; DRUG DESIGN; DRUG SYNERGISM; ESCHERICHIA COLI PROTEINS; HSP70 HEAT-SHOCK PROTEINS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROLINE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS SAPROPHYTICUS;

EID: 54049153545     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.07.016     Document Type: Article

References (28)

1. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Lorian V. (Ed). Antibiotics in laboratory medicine (1996), Lippincott Williams and Wilkins, Philadelphia, PA 52-111
2. Bagella L., Sun A., Tonini T., Abbadessa G., Cottone G., Paggi G.M., et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 26 (2007) 1829-1839
3. Bikker F.J., Kaman-van Zanten W.E., de Vries-van de Ruit A.M., Voskamp-Visser I., van Hooft P.A., Mars-Groenendijk R.H., et al. Evaluation of the antibacterial spectrum of drosocin analogues. Chem Biol Drug Des 68 (2006) 148-153
4. Bower M.A., Cudic M., Campbell W., Wade J.D., and Otvos Jr. L. Walking the fine line between intracellular and membrane activities of antibacterial peptides. Lett Pept Sci 10 (2004) 463-473
5. Bush K., Macielag M., and Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr Opin Microbiol 7 (2004) 466-476
6. Cudic M., Condie B.A., Weiner D.J., Lysenko E.S., Xiang Z.Q., Insug O., et al. Development of novel antibacterial peptides that kill resistant isolates. Peptides 23 (2002) 2071-2083
7. Cudic M., Lockatell C.V., Johnson D.E., and Otvos Jr. L. In vitro and in vivo activity of a designed antibacterial peptide analog against uropathogens. Peptides 24 (2003) 807-820
8. Eliopoulos G.M., and Moellering R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 3rd ed. (1991), Lippincott Williams & Wilkins, Baltimore, MD 432-492
9. Fernandez-Carneado J., Kogan M.J., Castel S., and Giralt E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl 43 (2004) 1811-1814
10. Fields G.B., and Noble R.L. Solid-phase peptide synthesis using 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35 (1990) 161-214
11. Ge Y., MacDonald D.L., Holroyd K.J., Thornsberry C., Wexler H., and Zasloff M. In vitro properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 43 (1999) 782-788
12. Hoffmann R., Bulet P., Urge L., and Otvos Jr. L. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim Biophys Acta 1426 (1999) 459-467
13. Hollośi M., Kawai M., and Fasman G.D. Studies on proline-containing tetrapeptide models of beta-turns. Biopolymers 24 (1985) 211-242
14. Kragol G., Hoffmann R., Chattergoon M.A., Lovas S., Cudic M., Bulet P., et al. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur J Biochem 269 (2002) 4226-4237
15. Kragol G., Lovas S., Varadi G., Condie B.A., Hoffmann R., and Otvos Jr. L. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 40 (2001) 3016-3026
16. Leng B., Meyers B.R., Hirschman S.Z., and Keusch G.T. Susceptibilities of gram-negative bacteria to combinations of antimicrobial agents in vitro. Antimicrob Agents Chemother 8 (1975) 164-171
17. Levy S.B., and Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10 (2004) S122-129
18. Lopez Ferreira N., and Alix J.H. The DnaK chaperone is necessary for α-complementation of β-galactosidase in Escherichia coli. J Bacteriol 184 (2002) 7047-7054
19. Noto P.B., Abbadessa G., Cassone M., Mateo G.D., Agelan A., Wade J.D., et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci 17 (2008) 1249-1255
20. Otvos Jr. L., de Olivier Inacio V., Wade J.D., and Cudic P. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob Agents Chemother 50 (2006) 3146-3149
21. Otvos Jr. L., de Olivier Inacio V., Rogers M.E., Consolvo P.J., Condie B.A., Lovas S., et al. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 39 (2000) 14150-14159
22. Otvos Jr. L., Snyder C., Condie B.A., Bulet P., and Wade J.D. Chimeric antimicrobial peptides exhibit multiple modes of action. Int J Pept Res Ther 11 (2005) 29-42
23. Otvos Jr. L., Wade J.D., Lin F., Condie B.A., Hanrieder J., and Hoffmann R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J Med Chem 48 (2005) 5349-5359
24. Raz R., Colodner R., and Kunin C.M. Who are you, Staphylococcus saprophyticus?. Clin Infect Dis 40 (2005) 896-898
25. Rothbard J.B., Kreider E., VanDeusen C.L., Wright L., Wylie B.L., and Wender P.A. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45 (2002) 3612-3618
26. Serra P., Brandimarte C., Martino P., Carlone S., and Giunchi G. Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies. Arch Intern Med 137 (1977) 1562-1567
27. Tarasi A., Cassone M., Monaco M., Tarasi D., Pompeo M.E., and Venditti M. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. J Chemother 15 (2003) 239-243
28. Weber J.T., and Courvalin P. An emptying quiver: antimicrobial drugs and resistance. Emerg Infect Dis 11 (2005) 791-793